JP2005507647A - 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド - Google Patents

細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド Download PDF

Info

Publication number
JP2005507647A
JP2005507647A JP2003514001A JP2003514001A JP2005507647A JP 2005507647 A JP2005507647 A JP 2005507647A JP 2003514001 A JP2003514001 A JP 2003514001A JP 2003514001 A JP2003514001 A JP 2003514001A JP 2005507647 A JP2005507647 A JP 2005507647A
Authority
JP
Japan
Prior art keywords
peptide
ser
ntp
amino acid
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003514001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507647A5 (enExample
Inventor
アヴァーバック，ポール・エイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nymox Corp
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of JP2005507647A publication Critical patent/JP2005507647A/ja
Publication of JP2005507647A5 publication Critical patent/JP2005507647A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
JP2003514001A 2001-07-19 2002-07-19 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド Pending JP2005507647A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30615001P 2001-07-19 2001-07-19
US30616101P 2001-07-19 2001-07-19
US33147701P 2001-11-16 2001-11-16
PCT/CA2002/001105 WO2003008443A2 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011035954A Division JP2011152133A (ja) 2001-07-19 2011-02-22 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Publications (2)

Publication Number Publication Date
JP2005507647A true JP2005507647A (ja) 2005-03-24
JP2005507647A5 JP2005507647A5 (enExample) 2006-01-05

Family

ID=27405149

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003514001A Pending JP2005507647A (ja) 2001-07-19 2002-07-19 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2003514002A Expired - Lifetime JP4587667B2 (ja) 2001-07-19 2002-07-19 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
JP2011035954A Pending JP2011152133A (ja) 2001-07-19 2011-02-22 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2013078281A Expired - Lifetime JP5622885B2 (ja) 2001-07-19 2013-04-04 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2003514002A Expired - Lifetime JP4587667B2 (ja) 2001-07-19 2002-07-19 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
JP2011035954A Pending JP2011152133A (ja) 2001-07-19 2011-02-22 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2013078281A Expired - Lifetime JP5622885B2 (ja) 2001-07-19 2013-04-04 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Country Status (22)

Country Link
US (2) US7192929B2 (enExample)
EP (2) EP1417228B1 (enExample)
JP (4) JP2005507647A (enExample)
KR (2) KR100966232B1 (enExample)
CN (1) CN100475843C (enExample)
AT (1) ATE353914T1 (enExample)
AU (2) AU2002319050B2 (enExample)
BR (2) BR0211199A (enExample)
CA (2) CA2453967C (enExample)
CY (1) CY1108009T1 (enExample)
DE (2) DE60217507T2 (enExample)
DK (1) DK1417228T3 (enExample)
EA (1) EA006603B1 (enExample)
ES (2) ES2281529T3 (enExample)
IL (2) IL159903A0 (enExample)
MX (1) MXPA04000561A (enExample)
NO (1) NO333999B1 (enExample)
NZ (2) NZ531114A (enExample)
PL (1) PL207588B1 (enExample)
PT (1) PT1417228E (enExample)
WO (2) WO2003008444A2 (enExample)
ZA (1) ZA200401320B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011152133A (ja) * 2001-07-19 2011-08-11 Nymox Corp 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
ES2295347T3 (es) * 2001-03-08 2008-04-16 Nymox Pharmaceutical Corporation Uso de proteinas de la cadena neural para tratar tumores.
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
ATE445714T1 (de) * 2001-12-04 2009-10-15 Millennium Pharm Inc 15603, ein mitglied der humanen ionenkanal- familie
US20080227125A1 (en) * 2003-07-15 2008-09-18 Guilaine Argoud-Puy Secreted Polypeptide Species Reduced in Cardiovascular Disorders
JP2007533596A (ja) * 2003-07-15 2007-11-22 ナショナル・リサーチ・カウンシル・オブ・カナダ 異常増殖性皮膚細胞を特徴とする状態の処置のためのヒト副甲状腺ホルモンの環状アナログ
WO2005075647A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
US20060173490A1 (en) 2005-02-01 2006-08-03 Boston Scientific Scimed, Inc. Filter system and method
AU2007219669A1 (en) 2006-02-28 2007-09-07 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP2007410A4 (en) * 2006-03-10 2009-10-21 Nymox Corp PROCESS FOR PREVENTING OR REDUCING THE RISK OF CANCER OR INCIDENCE WITH PEPTIDES BASED ON NEURAL THREAD PROTEIN
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP3192523B1 (en) * 2007-10-25 2020-09-16 Toray Industries, Inc. Immune response inducer
JP5572938B2 (ja) * 2007-10-25 2014-08-20 東レ株式会社 免疫誘導剤
WO2009070650A1 (en) * 2007-11-26 2009-06-04 The Research Foundation Of State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
RU2545347C2 (ru) * 2008-04-24 2015-03-27 Теримьюнекс Фармасьютикалз, Инк. Пептидил-диацилглицериды
IL319612A (en) 2010-09-29 2025-05-01 Seagen Inc Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
US20160215031A1 (en) * 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en) * 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) * 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
CN112236162A (zh) 2018-04-06 2021-01-15 昂科莱奇公司 用于裂解选择性癌细胞的组合物
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
CA3121573A1 (en) 2018-12-03 2020-06-11 Agensys, Inc. Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
WO2000000157A2 (en) * 1998-06-26 2000-01-06 Georgetown University Medical Center Use of tempo and tempo derivatives for inducing cell death
WO2000018426A1 (en) * 1998-09-30 2000-04-06 The Institute Of Physical And Chemical Research Apoptosis inducers
WO2000034477A2 (en) * 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
WO2000041497A2 (en) * 1999-01-11 2000-07-20 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378924B1 (en) 1988-12-21 1996-11-13 The General Hospital Corporation Detection of neurological disease or dysfunction
CA2282729A1 (en) * 1997-02-26 1998-09-03 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
AU3517000A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. 50 human secreted proteins
EP1171457A1 (en) * 1999-03-19 2002-01-16 Human Genome Sciences, Inc. 46 human secreted proteins
JP2002541833A (ja) * 1999-03-26 2002-12-10 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４９個のヒト分泌タンパク質
JP2002539842A (ja) * 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４５個のヒト分泌タンパク質
EP1220947A2 (en) 1999-03-26 2002-07-10 Human Genome Sciences, Inc. 50 human secreted proteins
CN1300779A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300783A (zh) 1999-12-23 2001-06-27 上海生元基因开发有限公司 新的人神经元线蛋白及其编码序列
EP1307488A2 (en) * 2000-06-26 2003-05-07 Millennium Pharmaceuticals, Inc. A human calcium channel protein and uses thereof
CN1352145A (zh) * 2000-11-10 2002-06-05 上海博德基因开发有限公司 一种新的多肽——锌指蛋白14.08和编码这种多肽的多核苷酸
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
ATE350396T1 (de) * 2001-05-25 2007-01-15 Nymox Corp Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
EA006603B1 (ru) * 2001-07-19 2006-02-24 Наймокс Корпорейшн Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
US5948888A (en) * 1988-12-21 1999-09-07 The General Hospital Corporation Neural thread protein gene expression and detection of Alzheimer's disease
WO2000000157A2 (en) * 1998-06-26 2000-01-06 Georgetown University Medical Center Use of tempo and tempo derivatives for inducing cell death
WO2000018426A1 (en) * 1998-09-30 2000-04-06 The Institute Of Physical And Chemical Research Apoptosis inducers
WO2000034477A2 (en) * 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
WO2000041497A2 (en) * 1999-01-11 2000-07-20 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011152133A (ja) * 2001-07-19 2011-08-11 Nymox Corp 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Also Published As

Publication number Publication date
CN100475843C (zh) 2009-04-08
AU2002319049B2 (en) 2007-10-25
NO333999B1 (no) 2013-11-11
AU2002319050B2 (en) 2008-09-11
EP1417227A2 (en) 2004-05-12
JP2005506061A (ja) 2005-03-03
ZA200401320B (en) 2005-01-26
JP4587667B2 (ja) 2010-11-24
KR20040026686A (ko) 2004-03-31
MXPA04000561A (es) 2005-02-17
CA2453967A1 (en) 2003-01-30
DK1417228T3 (da) 2007-06-04
JP5622885B2 (ja) 2014-11-12
EP1417227B1 (en) 2007-01-10
KR20040018481A (ko) 2004-03-03
WO2003008443A2 (en) 2003-01-30
BR0211200A (pt) 2004-09-28
ATE353914T1 (de) 2007-03-15
DE60218179T2 (de) 2007-11-22
WO2003008444A3 (en) 2003-11-20
CA2453967C (en) 2014-01-07
NZ531115A (en) 2005-03-24
WO2003008443A3 (en) 2003-11-27
NO20040222L (no) 2004-03-19
IL159903A (en) 2010-02-17
BRPI0211200B1 (pt) 2020-03-17
US20030109437A1 (en) 2003-06-12
EA006603B1 (ru) 2006-02-24
EA200400205A1 (ru) 2004-06-24
IL159903A0 (en) 2004-06-20
WO2003008444A2 (en) 2003-01-30
KR101005130B1 (ko) 2011-01-04
US7241738B2 (en) 2007-07-10
DE60217507T2 (de) 2007-11-15
EP1417228A2 (en) 2004-05-12
ES2281528T3 (es) 2007-10-01
DE60218179D1 (de) 2007-03-29
CN1649895A (zh) 2005-08-03
KR100966232B1 (ko) 2010-06-25
JP2011152133A (ja) 2011-08-11
CA2453965A1 (en) 2003-01-30
PL207588B1 (pl) 2011-01-31
EP1417228B1 (en) 2007-02-14
BR0211199A (pt) 2004-10-26
CA2453965C (en) 2016-01-19
ES2281529T3 (es) 2007-10-01
US7192929B2 (en) 2007-03-20
CY1108009T1 (el) 2013-09-04
PL368912A1 (en) 2005-04-04
US20030096756A1 (en) 2003-05-22
NZ531114A (en) 2006-12-22
BRPI0211200B8 (pt) 2021-07-27
JP2013215191A (ja) 2013-10-24
DE60217507D1 (de) 2007-02-22
PT1417228E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
JP5622885B2 (ja) 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP4717349B2 (ja) 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
JP4584573B2 (ja) 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
AU2002319049A1 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US20080176805A1 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
AU2002319050A1 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
AU2002256587A1 (en) Peptides derived from neural thread proteins and their medical use
EP1847550A2 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
HK1110083A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090902

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101022